KRAS and non-small cell lung carcinoma: In NSCLC cells harboring a KRAS mutation (G12C, Q61H and G12R), oncogenic KRAS can directly influence the activation of p38α, sustaining cell proliferation even in the presence of MEK inhibition (Sunaga et al., 2019).